Sixty-five percent of recurrence cases were retreated and the treatment duration (13.1 months) approximated the PFS of erlotinib in a de novo metastatic EGFR-mutant population, which implied that the long-term adjuvant TKI could be safe and that the tumor would still be sensitive to EGFR TKIs even after relapse following adjuvant erlotinib use. Here, EGFR is linked to neoplasm.